Axogen, Inc. Facing Securities Fraud Investigation – Reach out to DJS Law Group for assistance

The DJS Law Group is currently conducting an investigation regarding potential violations of securities laws by Axogen, Inc. This investigation aims to determine if the Company made any misleading statements or failed to disclose crucial information that could impact investors. Axogen recently announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months, leading to a significant decline in the company’s shares on the same day.

Investors who have incurred losses due to this issue are encouraged to get in touch with our firm to explore their options further. The core focus of the DJS Law Group is to optimize investor returns through a combination of strategic guidance and forceful representation. Our specialization lies in securities class actions, corporate governance litigation, and both domestic and international M&A appraisals. The clients we serve are among the most prominent and sophisticated hedge funds and alternative asset managers worldwide. We value the litigation claims of our clients as precious assets that require attentive care, dedication, and tangible outcomes.

It is important to note that this press release may be viewed as Attorney Advertising in certain jurisdictions based on the prevailing laws and ethical regulations. For any inquiries or to discuss your rights as an investor in Axogen, please reach out to David J. Schwartz at the DJS Law Group. You can contact us via phone at 914-206-9742 or email us at [email protected]

In the pursuit of justice and fairness for investors, the DJS Law Group is committed to conducting a thorough investigation to uncover any potential securities laws violations by Axogen, Inc., ensuring that affected shareholders have a fair chance to seek redress for any losses incurred.